Shots:
- The EC has approved Lupin’s Ranluspec, in both vial and PFS forms, a biosimilar version of Lucentis (ranibizumab)
- Ranibizumab is a recombinant humanized IgG1 antibody fragment that inhibits VEGF-A and is used to treat wet AMD, macular edema due to retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization
- Sandoz and Lupin Limited partnered in August 2025 to develop and commercialize a ranibizumab biosimilar. Sandoz holds exclusive EU rights to Ranluspec (excluding Germany) and semi-exclusive rights in France, while commercializing Epruvy (ranibizumab) in Germany under a separate agreement
Ref: Sandoz | Image: Sandoz and Lupin | Press Release
Related News: Sandoz Receives EC Approval of Ondibta (Biosimilar, Lantus and SoloStar)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
